Stock Events

Sage Therapeutics 

€7.96
38
+€0+0% Tuesday 13:57

Statistics

Day High
7.96
Day Low
7.82
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
514.65M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q1 2024
Q2 2024
Q3 2024
-3.37
-2.43
-1.49
-0.55
Expected EPS
-1.542392
Actual EPS
-1.53

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SG7.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap4.68B
Alkermes competes in the development of treatments for central nervous system (CNS) disorders, similar to Sage's focus on brain health disorders.
Acadia Pharmaceuticals
ACAD
Mkt Cap2.75B
Acadia Pharmaceuticals focuses on the development of drugs for central nervous system disorders, directly competing with Sage's portfolio.
BridgeBio Pharma
BBIO
Mkt Cap5.24B
BridgeBio Pharma targets genetic diseases and cancers, including CNS disorders, overlapping with Sage's therapeutic areas.
Biogen
BIIB
Mkt Cap29.83B
Biogen has a strong focus on neurology and multiple sclerosis treatments, competing with Sage in the neurotherapeutics space.
Sage Therapeutics
SAGE
Mkt Cap514.65M
Sage Therapeutics directly competes with itself through its diverse pipeline in CNS disorders, reflecting internal competition and portfolio diversification.
Jazz Pharmaceuticals
JAZZ
Mkt Cap7.16B
Jazz Pharmaceuticals has a portfolio that includes CNS treatments, making it a competitor in the neuropharmacology market.
Novartis
NVS
Mkt Cap244.75B
Novartis offers a broad range of healthcare solutions including treatments for neurological conditions, competing with Sage in the neurology space.
Pfizer
PFE
Mkt Cap164.39B
Pfizer has a diversified portfolio that includes CNS drugs, competing with Sage in the broader pharmaceutical market.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap21.38B
Teva Pharmaceutical Industries specializes in generic and specialty medicines, including CNS treatments, competing with Sage's specialized focus.
Lilly(Eli) &
LLY
Mkt Cap864.43B
Eli Lilly and Company has a strong presence in the psychiatric and neurological disorder treatment market, directly competing with Sage Therapeutics.

Analyst Ratings

11.42Average Price Target
The highest estimate is €25.
From 14 ratings within the last 6 months. This is not an investment recommendation.
Buy
7%
Hold
71%
Sell
21%

About

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Mr. Barry E. Greene
Employees
487
Country
US
ISIN
US78667J1088
WKN
000A117WF

Listings